One Hotel Drive,

Boston,

Massachusetts,

US,

ZIP: 02128

Phone: +16174554188

The Inaugural Gene Therapy Potency Summit (August 29-31) is dedicated to providing you with tools to identify, characterize and measure potency, enabling you to take tactical insights back to your team. The content will focus on the "sweet spot" of drug development where potency is most critical - pre-clinical development through to commercialization.

This is the only industry-led event dedicated to covering all challenges associated with potency for gene therapy drug developers specifically. We will unite with 60+ analytical, bioassay, Quality Control, regulatory and CMC experts to bring together content that gives actionable insights by combining both strategic and technical content.

URLs:
Brochure: https://go.evvnt.com/1720286-0?pid=1052
Tickets: https://go.evvnt.com/1720286-2?pid=1052

Prices:
Full Conference Access - Drug Developers: USD 4297.00,
Conference Only - Drug Developers: USD 2999.00,
Full Conference Access - Solution Provider: USD 5297.00,
Conference Only - Solution Provider: USD 3799.00,
Full Conference Access - Academic Institutes and Not-for-Profit: USD 3697.00,
Conference Only - Academic Institutes and Not-for-Profit: USD 2599.00

Speakers: Pankaj Mandal, FDA, Cullen Mason, Biogen, Dorota Bulik, Ultragenyx Pharmaceutical, Ilya Shestopalov, bluebird bio, Isaac Hutchinson, Johnson and Johnson Services,  Katharine Chambers, Abeona Therapeutics, Mindy Chou, Biogen, Mohd Akhlakur Rahman, Spark Therapeutics, Niranjan Kumar, Absinc Group, Parris Farr, Farr Consulting, Russell Beste, Principal Consultant, Scott Burger, Advanced Cell and Gene Therapy, Sheetal Bhan, Sanofi, Shilpa Suravajhala, bluebird bio, Stephanie Whipple, Sanofi, Susan Sleep, AGTC, Uditha deAlwis, Sarepta Therapeutics, Win Cheung, REGENXBIO, Xiaohui Lu, CRISPR Therapeutics